Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Spyre Therapeutics Inc.
SYRECurrent price
29.2 USD
-2.15 USD (-6.86%)
Last closed
31.27 USD
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 035 389 824 USD
Yield for 12 month
+192.29 %
1Y
3Y
5Y
10Y
15Y
SYRE
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. Address: 221 Crescent Street, Waltham, MA, United States, 02453
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
47.63 USDP/E ratio
3.6341Dividend Yield
–Current Year
+886 000 USD
Last Year
+2 329 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-78 000 USD
Last Year
+365 000 USD
Current Quarter
–
Last Quarter
–
Key Figures SYRE
1 year
3 years
5 years
10 years
EBITDA
-194 508 992 USD
Operating Margin TTM
PE Ratio
3.6341
Return On Assets TTM
-38.81 %
PEG Ratio
–
Return On Equity TTM
-91.62 %
Wall Street Target Price
47.63 USD
Revenue TTM
–
Book Value
3.34 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
10.89 USD
Diluted Eps TTM
10.89 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SYRE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SYRE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:25
Payout Ratio
–
Last Split Date
08.09.2023
Dividend Date
–
Stock Valuation SYRE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
3.6341
Forward PE
–
Enterprise Value Revenue
1964.9063
Price Sales TTM
2209.9204
Enterprise Value EBITDA
-7.9561
Price Book MRQ
9.3125
Financials SYRE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SYRE
For 52 weeks
8.75 USD
47.97 USD
50 Day MA
30.76 USD
Shares Short Prior Month
8 644 070
200 Day MA
31.06 USD
Short Ratio
13.78
Shares Short
8 413 483
Short Percent
19.53 %
BeatStart